FDA Warns CardioMEMS for Recommendations to Investigators
The FDA handed Atlanta-based CardioMEMS a warning letter for deviations related to a clinical investigation and premarket approval application (PMA) for its CardioMEMS HF Pressure Measurement System.
According to the June 5 letter posted to the FDA’s website Sept. 25, CardioMEMS failed to submit an accurate investigational plan describing how the Champion heart failure monitoring system (CHAMPION) study would be conducted. Specifically, the protocol did not indicate that the company would make recommendations to investigators about medical management.
That fact was mentioned in an executive summary that CardioMEMS’ presented to the Circulatory Systems Device Panel for a Dec. 8, 2011, meeting on the implantable heart device, as well as a 2007 email to the FDA, the letter notes.
Having a good laboratory practices (GLP) in place is paramount to passing every benchmark the FDA puts in place for a successful clinical trial. FDAnews’ GLP Compliance Strategies: 10-Steps to an Audit-Ready Lab helps you put your laboratory on the path to compliance by focusing on 10 key topics.
By following the structure laid out in this book, you’ll be sure to have an audit-ready lab you can be confident in, and take the uncertainty out of a visit from any auditor, inspector or potential client.
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!